LEADER 01167nam0 22002771i 450 001 UON00466242 005 20231205105145.136 100 $a20160401d1953 |0itac50 ba 101 $afre 102 $aFR 105 $a|||| ||||| 200 1 $aMax Jacob$fune etude par Andre Billy$gavec des lettres inedites du poete a Guillaume Apollinaire, un choix de poemes, des inedits, des manuscrits, des dessins, des portraits, une bibliographie 210 $aParis$cSeghers$d1953 215 $a211 p., 2 c. di tav.$cill.$d16 cm. 410 1$1001UON00275327$12001 $aPočtes d'aujourd'hui$1210 $aParis$cSeghers$v3 606 $aJACOB MAX$3UONC085386$2FI 620 $aFR$dParis$3UONL002984 700 1$aBILLY$bAndré$3UONV142991$0456459 702 1$aAPOLLINAIRE$bGuillaume$3UONV136963 712 $aSeghers$3UONV248119$4650 801 $aIT$bSOL$c20240220$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00466242 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI Francese 4 P.A. JAC $eSI MR 37405 7 996 $aMax Jacob$9913364 997 $aUNIOR LEADER 02852oas 2201093 a 450 001 9910144569503321 005 20251105213014.0 011 $a1557-8852 035 $a(DE-599)ZDB2520571-7 035 $a(OCoLC)45694108 035 $a(CONSER) 2005212454 035 $a(CKB)954925607868 035 $a(EXLCZ)99954925607868 100 $a20010110a19969999 sy a 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCancer biotherapy & radiopharmaceuticals 210 $aNew Rochelle, NY $cMary Ann Liebert, Inc 300 $aRefereed/Peer-reviewed 311 08$a1084-9785 517 3 $aCancer biotherapy and radiopharmaceuticals 606 $aCancer$xTreatment$vPeriodicals 606 $aRadiopharmaceuticals$vPeriodicals 606 $aBiological products$xTherapeutics$vPeriodicals 606 $aBiological Factors$xtherapeutic use 606 $aNeoplasms$xtherapy 606 $aRadioisotopes$xtherapeutic use 606 $aBiological Products$xtherapeutic use 606 $aCancer$xTraitement$vPe?riodiques 606 $aRadiopharmaceutiques$vPe?riodiques 606 $aCancer$xTreatment$2fast$3(OCoLC)fst00845538 606 $aRadiopharmaceuticals$2fast$3(OCoLC)fst01088327 608 $aPeriodical. 608 $aPeriodicals.$2fast 608 $aPeriodicals.$2lcgft 615 0$aCancer$xTreatment 615 0$aRadiopharmaceuticals 615 0$aBiological products$xTherapeutics 615 2$aBiological Factors$xtherapeutic use. 615 2$aNeoplasms$xtherapy 615 2$aRadioisotopes$xtherapeutic use. 615 2$aBiological Products$xtherapeutic use. 615 6$aCancer$xTraitement 615 6$aRadiopharmaceutiques 615 7$aCancer$xTreatment. 615 7$aRadiopharmaceuticals. 676 $a616 801 0$bF#A 801 1$bF#A 801 2$bOCLCQ 801 2$bOCLCS 801 2$bNSD 801 2$bOCLCQ 801 2$bMXC 801 2$bLGG 801 2$bPFM 801 2$bGBT 801 2$bOCLCQ 801 2$bFJM 801 2$bOCLCQ 801 2$bSERSO 801 2$bOCLCO 801 2$bDLC 801 2$bSERSO 801 2$bEUW 801 2$bOCLCQ 801 2$bU3W 801 2$bOCLCO 801 2$bOCLCF 801 2$bOCLCO 801 2$bMOW 801 2$bAU@ 801 2$bOCLCO 801 2$bWYU 801 2$bOCLCO 801 2$bUKMGB 801 2$bOCLCO 801 2$bOCLCA 801 2$bUHL 801 2$bOCLCQ 801 2$bOCLCO 801 2$bOCLCQ 801 2$bIOY 801 2$bOCLCL 801 2$bSFB 801 2$bSRU 801 2$bOCLCQ 906 $aJOURNAL 912 $a9910144569503321 996 $aCancer biotherapy & radiopharmaceuticals$92088307 997 $aUNINA